Evidence map›Paper›PMID 40772765›Full record

ReviewFuture science OA2025

Liquid biopsy - a narrative review with an update on current US governmental clinical trials targeting immunotherapy.

Fan Shen, Samar A Zailaie, Brian Chiu, Anthony Magliocco, Consolato M Sergi

Abstract readReview
In one paragraph

Review in Future science OA, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. [Liquid Biopsy Revolutionizes the Precise Management of Tumors Across the Entire Course: Current Situation and Future Prospects].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2026
    Pooled it
  2. Review
  3. Review
  4. Review
  5. Artificial Intelligence and the future of clinical trials.Contemporary clinical trials communications · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Fan ShenDepartment of Laboratory Medicine, Stollery Children's Hospital, University of Alberta, Edmonton, AB, Canada.
Samar A ZailaieResearch Center, King Faisal Specialist Hospital & Research Center-Jeddah (KFSHRC-J), Jeddah, Kingdom of Saudi Arabia.
Brian ChiuDepartment of Laboratory Medicine, Stollery Children's Hospital, University of Alberta, Edmonton, AB, Canada.
Anthony MaglioccoProtean BioDiagnostics Inc, Orlando, FL, USA.
Consolato M SergiDepartment of Laboratory Medicine, Stollery Children's Hospital, University of Alberta, Edmonton, AB, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimThis study aims to present a comprehensive international analysis of the existing techniques used in liquid biopsies and their use in isolating tumor markers to detect, predict, and monitor the results of cancer treatment. MATERIALS AND

methodsWe conducted a narrative review using a scoping review model based on three databases, including PubMed/Medline, Scopus, and Cochrane. The search criteria included all articles on liquid biopsy of the last five years (June 30th, 2023-Oct 30, 2024) ((liquid Biopsy) AND (("2023/06/30"[Date - Publication]: "2024/10/30"[Date - Publication]))). We also approached gray literature on this topic. We focused on review articles as an eligibility criterion for this narrative review, but we also carried out a United States registered clinical trials review targeting immunotherapy and liquid biopsy with the limitation "recruiting" and/or "not yet recruiting" (updated on March 31, 2025).

resultsWe screened 2645 articles from PubMed/Medline, Scopus, and Cochrane and 45 articles from the gray literature. We retrieved the full text for 325 articles. Liquid biopsies involve the extraction of tumor-derived components such as circulating tumor cells, circulating tumor DNA, and tumor extracellular vesicles from the bodily fluids of cancer patients. We found 25 United States registered governmental clinical trials targeting immunotherapy and liquid biopsy, of which 20 trials are recruiting and five trials are not yet recruiting. DISCUSSION: Developments in medicine have led to a more comprehensive understanding of tumor features, including tumor load, tumor staging, heterogeneity, gene mutations, and clonal evolution. The utilization of liquid biopsies from cancer patients has provided novel opportunities for detection and ongoing monitoring, precision medicine-based therapy, and identification of markers for therapeutic resistance.

Indexed as

cancercirculating tumor cellscirculating tumor DNALiquid biopsyprecision medicineproteomicsRNAtumor extracellular vesicles

Identifiers

PMID40772765
PMCPMC12333414

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.